Search alternatives:
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
w decrease » we decrease (Expand Search), _ decrease (Expand Search), _ decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
Showing 61 - 80 results of 108,899 for search '(( 4 w decrease ) OR ( 5 ((((step decrease) OR (mean decrease))) OR (a decrease)) ))', query time: 1.75s Refine Results
  1. 61
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 62
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 63
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 64
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 65
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 66
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 67
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 68
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 69
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 70
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 71
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 72
    Overview of the six original ACTIV-3/TICO trials.

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 73
    Deletion of <i>sagA</i> alone results in a decrease in nasopharyngeal infection.

    Deletion of <i>sagA</i> alone results in a decrease in nasopharyngeal infection. by Blake A. Shannon (14197601)

    Published 2024
    Save to List
    Saved in:
  14. 74
    PTH decreased cell apoptosis in a Flt-3L expanded population.

    PTH decreased cell apoptosis in a Flt-3L expanded population. by Flavia Q. Pirih (360515)

    Published 2013
    Save to List
    Saved in:
  15. 75
    Rdh10a deficient embryos have decreased expression of RA signaling responsive genes.

    Rdh10a deficient embryos have decreased expression of RA signaling responsive genes. by Enrico D’Aniello (798447)

    Published 2015
    “…<p>(A-F) ISH for <i>cyp26a1</i>, <i>hoxb5b</i>, <i>and dhrs3a</i> expression in control sibling and Rdh10a deficient embryos. …”
    Save to List
    Saved in:
  16. 76
    SARS-CoV-2 decreases excitatory synapses, while influenza A does not induce cell death in BCO.

    SARS-CoV-2 decreases excitatory synapses, while influenza A does not induce cell death in BCO. by Pinar Mesci (14053895)

    Published 2022
    Save to List
    Saved in:
  17. 77
    Thrombin-induced decreased lamellipodia protrusion frequency and actin stress fiber formation.

    Thrombin-induced decreased lamellipodia protrusion frequency and actin stress fiber formation. by Jerome W. Breslin (548352)

    Published 2015
    “…<i>B</i>. Thrombin initially decreased the mean protrusion frequency of local lamellipodia. …”
    Save to List
    Saved in:
  18. 78
    Cannabis smoke exposure decreases locomotor activity and rearing in the small open field.

    Cannabis smoke exposure decreases locomotor activity and rearing in the small open field. by Adriaan W. Bruijnzeel (2605954)

    Published 2016
    Save to List
    Saved in:
  19. 79
    MVEC microvessel formation is restricted in hydrogels exhibiting increased stiffness or decreased concentration of adhesive peptides.

    MVEC microvessel formation is restricted in hydrogels exhibiting increased stiffness or decreased concentration of adhesive peptides. by Rebecca A. Scott (488956)

    Published 2020
    “…An unpaired student’s t-test detect statistical significance, *p<0.05 for 7.5 wt% hydrogels containing 3 mM RGD relative to either (<b>A, C-F</b>) 15wt% hydrogels containing 3 mM RGD or (<b>G, I-L</b>) 7.5wt% hydrogels containing 1 mM RGD.…”
    Save to List
    Saved in:
  20. 80
    Cooperativity decreases with the expression level of CheA.

    Cooperativity decreases with the expression level of CheA. by Stephan Eismann (835052)

    Published 2015
    Save to List
    Saved in:

Search Tools: